IRST-IRCCS is a multispeciality cancer institute, founded in 2007, for the treatment of solid and haematological tumors through high-complexity clinical specialities: radiometabolic therapy, high-precision radiotherapy, cellular therapies and immunotherapy.
Research is one of the fundamental pillars of IRST – IRCCS and focuses on basic science, translational and clinical research and personalized risk assessment.
The aim of IRST – IRCCS is to strengthen the link between treatment and research, guaranteeing quality, originality, innovation and transferability of laboratory results to clinical practice.
IRST – IRCCS is situated in Meldola (Emilia Romagna – Italy), covering an area of over 1.1 million inhabitants and is fully integrated with National Health Service.
- This is what IRST-IRCCS brings to the ONCOVALUE consortium… IRST contributes its expertise in the ability to read and interpret real-world data, of which it has a wealth of knowledge to contribute to the advancement of new insights for the benefit of patients. Additionally, it is leveraging its knowledge in the field of AI to support the development of advanced systems for the use of RWD.
- IRST-IRCCS hopes that this consortium… will achieve the goal of expediting access to drugs for oncology patients through more efficient and timely evaluations by regulatory authorities, made possible thanks to the significant wealth of real-world data managed through the most sophisticated techniques available today, including AI.
